170 related articles for article (PubMed ID: 32166305)
1. Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs.
Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J
Clin Infect Dis; 2021 Apr; 72(8):1392-1400. PubMed ID: 32166305
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
[TBL] [Abstract][Full Text] [Related]
3. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study.
Artenie AA; Cunningham EB; Dore GJ; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Lacombe K; Stedman C; Litwin AH; Marks P; Matthews GV; Quiene S; Erratt A; Bruneau J; Grebely J
Clin Infect Dis; 2020 May; 70(11):2369-2376. PubMed ID: 31300820
[TBL] [Abstract][Full Text] [Related]
5. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
7. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era.
Ingiliz P; Wehmeyer MH; Boesecke C; Schulze Zur Wiesch J; Schewe K; Lutz T; Baumgarten A; Simon KG; Hueppe D; Rockstroh JK; Mauss S; Christensen S; ;
Clin Infect Dis; 2020 Aug; 71(5):1248-1254. PubMed ID: 31562816
[TBL] [Abstract][Full Text] [Related]
8. A Phylogenetic Analysis of Hepatitis C Virus Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.
Akiyama MJ; Lipsey D; Ganova-Raeva L; Punkova LT; Agyemang L; Sue A; Ramachandran S; Khudyakov Y; Litwin AH
J Infect Dis; 2020 Jul; 222(3):488-498. PubMed ID: 32150621
[TBL] [Abstract][Full Text] [Related]
9. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Milne R; Drost A; Barnett T; Lundgren K; Guarasci K; Grebely J; Fraser C
Int J Drug Policy; 2019 Oct; 72():106-113. PubMed ID: 31178254
[TBL] [Abstract][Full Text] [Related]
11. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.
Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P
Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391
[TBL] [Abstract][Full Text] [Related]
12. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
Graf C; Mücke MM; Dultz G; Peiffer KH; Kubesch A; Ingiliz P; Zeuzem S; Herrmann E; Vermehren J
Clin Infect Dis; 2020 May; 70(11):2355-2365. PubMed ID: 31513710
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
Muller A; Vlahov D; Akiyama MJ; Kurth A
Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
[TBL] [Abstract][Full Text] [Related]
15. Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England.
Hibbert M; Simmons R; Harris H; Desai M; Sabin CA; Mandal S
J Viral Hepat; 2023 Aug; 30(8):646-655. PubMed ID: 36929670
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ;
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):153-161. PubMed ID: 29310928
[TBL] [Abstract][Full Text] [Related]
17. The effects of needle-sharing and opioid substitution therapy on incidence of hepatitis C virus infection and reinfection in people who inject drugs.
Aitken CK; Agius PA; Higgs PG; Stoové MA; Bowden DS; Dietze PM
Epidemiol Infect; 2017 Mar; 145(4):796-801. PubMed ID: 27927256
[TBL] [Abstract][Full Text] [Related]
18. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
19. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis.
Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK
Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050
[TBL] [Abstract][Full Text] [Related]
20. Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ;
J Viral Hepat; 2024 Jan; 31(1):21-34. PubMed ID: 37936544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
